Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations.

abstract：:Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mes...

journal_title：Oncoimmunology

authors： Bertino P,Premeaux TA,Fujita T,Haun BK,Marciel MP,Hoffmann FW,Garcia A,Yiang H,Pastorino S,Carbone M,Niki T,Berestecky J,Hoffmann PR,Ndhlovu LC

更新日期：2019-04-17 00:00:00

abstract：:The intestinal microbiota plays a key role in the pathogenesis of acute graft-versus-host disease (aGVHD). High-dose conditioning regimens given prior to allogeneic hematopoietic stem cell transplantation (aHSCT) modulate the composition of gut microbiota and damage the gut epithelial barrier, resulting in increased s...

journal_title：Oncoimmunology

authors： Routy B,Letendre C,Enot D,Chénard-Poirier M,Mehraj V,Séguin NC,Guenda K,Gagnon K,Woerther PL,Ghez D,Lachance S

更新日期：2016-12-27 00:00:00

abstract：:Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

journal_title：Oncoimmunology

authors： Adamopoulou E,Naumann U

更新日期：2013-08-01 00:00:00

abstract：:Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell surface target to the...

journal_title：Oncoimmunology

authors： Thayaparan T,Petrovic RM,Achkova DY,Zabinski T,Davies DM,Klampatsa A,Parente-Pereira AC,Whilding LM,van der Stegen SJ,Woodman N,Sheaff M,Cochran JR,Spicer JF,Maher J

更新日期：2017-08-14 00:00:00

abstract：:Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

journal_title：Oncoimmunology

authors： Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

更新日期：2018-01-29 00:00:00

abstract：:Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

journal_title：Oncoimmunology

authors： Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

更新日期：2018-09-26 00:00:00

abstract：:Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer agents. Such an enthus...

journal_title：Oncoimmunology

authors： Aranda F,Vacchelli E,Eggermont A,Galon J,Sautès-Fridman C,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-12-01 00:00:00

abstract：:Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

journal_title：Oncoimmunology

authors： Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

更新日期：2017-06-20 00:00:00

abstract：:Surgical resection of the primary tumor provides the best chance of cure for patients with colorectal carcinoma (CRC). However, bacterial translocation during intestinal surgery has been correlated with poor long-term oncological outcome. Therefore, we investigated the influence of bacterial contamination during colon...

journal_title：Oncoimmunology

authors： Grewal S,Korthouwer R,Bögels M,Braster R,Heemskerk N,Budding AE,Pouw SM,van Horssen J,Ankersmit M,Meijerink J,van den Tol P,Oosterling S,Bonjer J,Gül N,van Egmond M

更新日期：2018-07-26 00:00:00

abstract：:Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of r...

journal_title：Oncoimmunology

authors： Putz EM,Schuster C,Sexl V

更新日期：2012-08-01 00:00:00

abstract：:Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microenvironment. In this...

journal_title：Oncoimmunology

authors： Hagihara K,Chan S,Zhang L,Oh DY,Wei XX,Simko J,Fong L

更新日期：2018-10-01 00:00:00

abstract：:The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can be associated with an IFNγ storm that induces in tumor cells the "adaptive immune resistance" characterized by the de-novo expression of Programm...

journal_title：Oncoimmunology

authors： Dondero A,Pastorino F,Della Chiesa M,Corrias MV,Morandi F,Pistoia V,Olive D,Bellora F,Locatelli F,Castellano A,Moretta L,Moretta A,Bottino C,Castriconi R

更新日期：2015-07-15 00:00:00

abstract：:Radiotherapy is an important therapeutic option for the treatment of cancer. Growing evidence indicates that, besides inducing an irreversible DNA damage, radiotherapy promotes tumor-specific immune response, which significantly contribute to therapeutic efficacy. We postulate that radiotherapy activates tumor-associa...

journal_title：Oncoimmunology

authors： Gupta A,Sharma A,von Boehmer L,Surace L,Knuth A,van den Broek M

更新日期：2012-12-01 00:00:00

abstract：:Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of ch...

journal_title：Oncoimmunology

authors： van Dodewaard-de Jong JM,Santegoets SJ,van de Ven PM,Versluis J,Verheul HM,de Gruijl TD,Gerritsen WR,van den Eertwegh AJ

更新日期：2015-12-21 00:00:00

abstract：:Cancer immunotherapy continues to make headway as a treatment for advanced stage tumors, revealing an urgent need to understand the fundamentals of anti-tumor immune responses. Noteworthy is a scarcity of data pertaining to the breadth and specificity of tumor-specific T cell responses in metastatic breast cancer. Aut...

journal_title：Oncoimmunology

authors： DeVette CI,Gundlapalli H,Lai SA,McMurtrey CP,Hoover AR,Gurung HR,Chen WR,Welm AL,Hildebrand WH

更新日期：2019-11-29 00:00:00

abstract：:Tumor infiltrating lymphocytes (TIL) in Epstein-Barr virus (EBV)-associated/microsatellite-unstable (MSI) gastric carcinomas (GC) constitute immune-active principal cellular components of tumor microenvironment and contribute to better prognosis. With the remarkable success of cancer immunotherapies, there is an urgen...

journal_title：Oncoimmunology

authors： Park C,Cho J,Lee J,Kang SY,An JY,Choi MG,Lee JH,Sohn TS,Bae JM,Kim S,Kim ST,Park SH,Park JO,Kang WK,Sohn I,Jung SH,Kang MS,Kim KM

更新日期：2017-08-10 00:00:00

abstract：:Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyz...

journal_title：Oncoimmunology

authors： Kreutzman A,Yadav B,Brummendorf TH,Gjertsen BT,Hee Lee M,Janssen J,Kasanen T,Koskenvesa P,Lotfi K,Markevärn B,Olsson-Strömberg U,Stentoft J,Stenke L,Söderlund S,Udby L,Richter J,Hjorth-Hansen H,Mustjoki S

更新日期：2019-07-13 00:00:00

abstract：:We have recently described two types of Langerhans cells (LCs), which develop via separate pathways in steady-state conditions and during inflammation. Here, we propose that these two types of LCs differ in their requirement for transforming growth factor β1 (TGFβ1), and we discuss how TGFβ1 impacts on the development...

journal_title：Oncoimmunology

authors： Seré K,Felker P,Hieronymus T,Zenke M

更新日期：2013-03-01 00:00:00

abstract：:Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows p...

journal_title：Oncoimmunology

authors： Chard LS,Lemoine NR,Wang Y

更新日期：2015-07-20 00:00:00

abstract：:Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. Based on our previous studies showing bendamustine with total body irradiation (B...

journal_title：Oncoimmunology

authors： Stokes J,Hoffman EA,Molina MS,Kummet N,Simpson RJ,Zeng Y,Katsanis E

更新日期：2020-04-30 00:00:00

abstract：:Renal cell carcinoma (RCC) is an immunogenic tumor, but uses several immune-suppressive mechanisms to shift the balance from tumor immune response toward tumor growth. Although RCC has traditionally been considered to be radiation resistant, recent evidence suggests that hypofractionated radiotherapy contributes to sy...

journal_title：Oncoimmunology

authors： De Wolf K,Vermaelen K,De Meerleer G,Lambrecht BN,Ost P

更新日期：2015-05-27 00:00:00

abstract：:The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a diffusion enhanced formulation, INT230-6, containing potent anti-cancer cytotoxic agents, was administered intratumorally into large (app...

journal_title：Oncoimmunology

authors： Bloom AC,Bender LH,Tiwary S,Pasquet L,Clark K,Jiang T,Xia Z,Morales-Kastresana A,Jones JC,Walters I,Terabe M,Berzofsky JA

更新日期：2019-07-16 00:00:00

abstract：:Programmed death ligand 1 (PD-L1) expression represents a mechanism of immune escape by inhibiting T cell immunity. This study systematically evaluated the expression of PD-L1, spatial distribution of CD3+ immune cells and the relationship of both factors to survival in nasopharyngeal carcinoma (NPC) patients. A total...

journal_title：Oncoimmunology

authors： Zhu Q,Cai MY,Chen CL,Hu H,Lin HX,Li M,Weng DS,Zhao JJ,Guo L,Xia JC

更新日期：2017-04-27 00:00:00

abstract：:To antagonize tumor-derived TGFβ contemporaneously to anticancer immunotherapy, we genetically engineered a fusion protein coupling IL-2 and the ectodomain of TGFβ receptor II (Fusion of Interleukin-2 and Soluble TGFβ receptor - a.k.a. FIST). FIST possesses intriguing gain-of-function properties and induces potent act...

journal_title：Oncoimmunology

authors： Penafuerte C,Galipeau J

更新日期：2012-03-01 00:00:00

abstract：:Pancreatic cancer is characterized by expanded stroma with marked fibrosis. In Ijichi et al., we show that inhibiting CXCR2 disrupts tumor-stromal interactions and improves survival of a genetically-engineered mouse model recapitulating human pancreatic cancer. Targeting CXCLs/CXCR2 axis in the tumor microenvironment ...

journal_title：Oncoimmunology

authors： Ijichi H

更新日期：2012-07-01 00:00:00

abstract：:DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFκB inflammatory cascades, leading to upregulation of integrin-αbβ3 on chemoresistant tumor cells. The integrin-αbβ3 is responsible for impeding tumor-specific ...

journal_title：Oncoimmunology

authors： Jinushi M

更新日期：2012-05-01 00:00:00

abstract：:Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

journal_title：Oncoimmunology

authors： Houot R,Kohrt H,Levy R

更新日期：2012-09-01 00:00:00

abstract：:Podoplanin (PDPN) has been proved to have significant immunoregulatory effects in several types of malignancies and is considered to be a novel immune checkpoint molecule. However, the clinical significance of PDPN and its potential influence on immune contexture in gastric cancer remain obscure. Here, we aimed to inv...

journal_title：Oncoimmunology

authors： Liu X,Cao Y,Lv K,Gu Y,Jin K,He X,Fang H,Fei Y,Shi M,Lin C,Liu H,Li H,He H,Xu J,Li R,Zhang H

更新日期：2020-11-13 00:00:00

abstract：:When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

journal_title：Oncoimmunology

authors： Su WP,Wang WJ,Sze CI,Chang NS

更新日期：2016-07-28 00:00:00

abstract：:Although the outcome of colorectal cancer (CRC) patients has improved significantly with the recent implementation of annual screening programs, reliable prognostic biomarkers are still needed due to the disease heterogeneity. Increasing pieces of evidence revealed an association between immune signature and CRC progn...

journal_title：Oncoimmunology

authors： Wu J,Zhao Y,Zhang J,Wu Q,Wang W

更新日期：2019-04-15 00:00:00